CLAIMS

1. Use of a pharmaceutical composition in the manufacture of a medicament for treating or putting an elderly solid cancer patient or a terminal solid cancer patient into remission, wherein the pharmaceutical composition comprises, as an active ingredient, (2S)-2-[(2S,3R)-3-amino-2-hydroxy-4-phenylbutanoylamino]-4-methylpentanoic acid or a pharmacologically acceptable salt thereof, wherein the active ingredient is to be administered to the elderly solid cancer patient or the terminal solid cancer patient at a dose of 10mg per administration once a day, and the elderly solid cancer patient is 70 years of age or older.

2. The use according to claim 1, wherein the elderly solid cancer patient or the terminal solid cancer patient has a 4 or higher neutrophil count to lymphocyte count ratio in peripheral blood, or a 1.5 or higher platelet count to lymphocyte count ratio in peripheral blood, or a normal range of 130000-350000 platelet counts/μL or a normal range of 2000-6800 neutrophil counts/mm^3 in peripheral blood.

3. The use according to claim 1 or 2, wherein the elderly solid cancer patient or the terminal solid cancer patient has colon or colorectal cancer, breast cancer, thyroid gland cancer, lung cancer, gallbladder/bile duct cancer, or renal cancer, or a metastatic cancer thereof.

4. Use of a combination drug in the manufacture of a medicament for treating or putting an elderly solid cancer patient or a terminal solid cancer patient into remission, wherein the combination drug comprises the pharmaceutical composition according to any one of claims 1 to 3, and an anticancer agent and/or a molecular targeted drug, and wherein the elderly solid cancer patient is 70 years of age or older.

5. Use of a kit preparation in the manufacture of a medicament for treating or putting an elderly solid cancer patient or a terminal solid cancer patient into remission, wherein the kit preparation comprises the pharmaceutical composition according to any one of claims 1 to 3, and an anticancer agent and/or a molecular targeted drug, and wherein the elderly solid cancer patient is 70 years of age or older.

6. The use according to claim 4 or 5, wherein the molecular targeted drug is Erlotinib, Afatinib, or Osimertinib.